Kei Namba
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
-
- Cancer Genomics and Diagnostics
Papers in
-
- Lung Cancer Treatments and Mutations 13
- Lung Cancer Diagnosis and Treatment 5
- Gastric Cancer Management and Outcomes 3
-
- PI3K/AKT/mTOR signaling in cancer 6
- Glycosylation and Glycoproteins Research 3
- Co-authors
- M. Kubo (2 shared papers)Hiromasa Yamamoto (28 shared papers)Junichi Soh (28 shared papers)Kazuhiko Shien (27 shared papers)Shinichi Toyooka (29 shared papers)Shuta Tomida (22 shared papers)Hidejiro Torigoe (20 shared papers)Hiroki Sato (19 shared papers)
- Journals
- Cancer Science (6 papers)Scientific Reports (3 papers)Cancer Research (3 papers)Journal of Thoracic Oncology (2 papers)Anticancer Research (2 papers)
- Partner nations
- JapanUnited StatesCanada
In The Last Decade
Kei Namba
41 papers receiving 650 citations
Peers
Comparison fields: 5 of 85
- Oncology 251
- Cancer Research 107
- Pulmonary and Respiratory Medicine 215
- Pharmacology 95
- Biochemistry 29
Countries citing papers authored by Kei Namba
This map shows the geographic impact of Kei Namba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Namba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Namba more than expected).
Fields of papers citing papers by Kei Namba
This network shows the impact of papers produced by Kei Namba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Namba. The network helps show where Kei Namba may publish in the future.
Co-authors
The 25 scholars most cited alongside Kei Namba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1981 | 127 | |
| 2 | 2018 | 71 | |
| 3 | 2018 | 55 | |
| 4 | 1983 | 37 | |
| 5 | 2018 | 35 | |
| 6 | 2019 | 30 | |
| 7 | 2017 | 29 | |
| 8 | 2016 | 22 | |
| 9 | 2017 | 22 | |
| 10 | 2018 | 21 | |
| 11 | 2018 | 20 | |
| 12 | 2019 | 20 | |
| 13 | 2019 | 19 | |
| 14 | 2018 | 19 | |
| 15 | 2019 | 17 | |
| 16 | 2024 | 14 | |
| 17 | Primary rhabdomyosarcoma of the tentorium with peculiar angiographic findings. | 1979 | 11 |
| 18 | 2020 | 10 | |
| 19 | 2018 | 9 | |
| 20 | 1996 | 9 |
About Kei Namba
Kei Namba is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Pathology and Forensic Medicine and Cancer Research, having authored 41 papers that have together received 668 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer Genomics and Diagnostics (5 papers), Lung Cancer Diagnosis and Treatment (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Gastric Cancer Management and Outcomes (3 papers) and Glycosylation and Glycoproteins Research (3 papers). The work is most often cited by research in Oncology (251 citations), Cancer Research (107 citations), Pulmonary and Respiratory Medicine (215 citations), Pharmacology (95 citations) and Biochemistry (29 citations). Kei Namba has collaborated with scholars based in Japan, United States and Canada. Frequent co-authors include M. Kubo, Hiromasa Yamamoto, Junichi Soh, Kazuhiko Shien, Shinichi Toyooka, Shuta Tomida, Hidejiro Torigoe, Hiroki Sato, Tsutomu Odani and T. Tani. Their work appears in journals such as Cancer Science, Scientific Reports, Cancer Research, Journal of Thoracic Oncology and Anticancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.